Kindeva Drug Delivery announced that it received a grant from a UK fund worth a $42.2 million (£33 million) investment.
The grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) aims to help Kindeva enhance inhaler manufacturing and sustainability. Funds improve Kindeva’s capability and capacity to manufacture the next generation of green pressurized metered-dose inhalers (pMDIs).
“This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the UK, as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products,” said Kindeva CCO David Stevens. “This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”
The investment supports the global development and manufacturing of inhalers using new, lower global warming potential propellants. It also creates and safeguards local jobs at the Loughborough and Clitheroe sites in the UK.
Kindeva also said the investment supports new manufacturing capability and capacity in Loughborough for next-generation green inhalers. It also backs green improvements to Kindeva’s underlying inhaler componentry supply chain in Clitheroe.
The investment helps pharmaceutical companies as they make green transitions with existing products, too, Kindeva said. It enables them to bring new green inhalers and respiratory therapies to patients.